{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:09:58Z","timestamp":1792271398413,"version":"4.4.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.urolonc.2026.111095","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T13:09:47Z","timestamp":1776172187000},"page":"86-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Concordance and prognostic value of antibody drug conjugate and checkpoint inhibition targets in matched bladder cancer specimens from transurethral resection of the bladder, radical cystectomy and lymphadenectomy"],"prefix":"10.1016","volume":"44","author":[{"given":"Daniel","family":"Uysal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Reible","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Wildner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Steidler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"St\u00f6th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Nientiedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Stefan","family":"Worst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Erben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Egen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Nitschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Brochhausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice Stephan","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Nuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Friedrich","family":"Kowalewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2026.111095_bib0001","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2026.111095_bib0002","article-title":"EV-302\/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC)","author":"Powles BPV","year":"2023","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111095_bib0003","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13046-015-0144-7","article-title":"Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer","volume":"34","author":"Nishiwada","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"issue":"46","key":"10.1016\/j.urolonc.2026.111095_bib0004","doi-asserted-by":"crossref","first-page":"43205","DOI":"10.1074\/jbc.M103810200","article-title":"Nectin4\/PRR4, a new afadin-associated member of the nectin family that trans-interacts with nectin1\/PRR1 through V domain interaction","volume":"276","author":"Reymond","year":"2001","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.urolonc.2026.111095_bib0005","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: a phase I study of single-agent Enfortumab Vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111095_bib0006","doi-asserted-by":"crossref","unstructured":"Powles T.H., Michiel; Loriot, Yohann; Bedke, Jens; P\u00e9rez-Valderrama, Bego\u00f1a; Iyer, Gopa, et al. EV-302: updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la\/mUC). Journal of Clinical Oncology. 43. doi: 10.1200\/JCO.2025.43.5_suppl.664.","DOI":"10.1200\/JCO.2025.43.5_suppl.664"},{"issue":"12","key":"10.1016\/j.urolonc.2026.111095_bib0007","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of Disitamab Vedotin in patients with Human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111095_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2026.111095_bib0009","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-4598-9-3","article-title":"Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer","volume":"9","author":"Kim","year":"2010","journal-title":"Mol Cancer"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111095_bib0010","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the Xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111095_bib0011","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"269","key":"10.1016\/j.urolonc.2026.111095_bib0012","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111095_bib0013","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111095_bib0014","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12885-022-09259-z","article-title":"Nectin-4 and DNA mismatch repair proteins expression in upper urinary tract urothelial carcinoma (UTUC) as a model for tumor targeting approaches: an ImGO pilot study","volume":"22","author":"Calandrella","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2026.111095_bib0015","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","author":"Klumper","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.urolonc.2026.111095_bib0016","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab Vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111095_bib0017","doi-asserted-by":"crossref","first-page":"167","DOI":"10.21873\/anticanres.16146","article-title":"Immunohistochemical analysis of HER2, EGFR, and nectin-4 expression in upper urinary tract urothelial carcinoma","volume":"43","author":"Hashimoto","year":"2023","journal-title":"Anticancer Res"},{"issue":"8","key":"10.1016\/j.urolonc.2026.111095_bib0018","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes","volume":"29","author":"Hoffman-Censits","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111095_bib0019","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s00292-018-0507-x","article-title":"[Predictive value of PD-L1 diagnostics]","volume":"39","author":"Schildhaus","year":"2018","journal-title":"Pathologe"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111095_bib0020","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000453670","article-title":"ERBB2 Expression as potential risk-stratification for early cystectomy in patients with pT1 bladder cancer and concomitant carcinoma in situ","volume":"98","author":"Breyer","year":"2017","journal-title":"Urol Int"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111095_bib0021","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1213\/ANE.0000000000002864","article-title":"Correlation coefficients: appropriate use and interpretation","volume":"126","author":"Schober","year":"2018","journal-title":"Anesth Analg"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111095_bib0022","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/jso.26973","article-title":"Outcomes of robotic-assisted versus open radical cystectomy in a large-scale, contemporary cohort of bladder cancer patients","volume":"126","author":"Hoeh","year":"2022","journal-title":"J Surg Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111095_bib0023","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab Vedotin plus Pembrolizumab in previously untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111095_bib0024","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/his.15130","article-title":"Associations of TACSTD2\/TROP2 and NECTIN-4\/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts","volume":"84","author":"Bahlinger","year":"2024","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111095_bib0025","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.euf.2023.12.002","article-title":"The financial burden of guideline-recommended cancer medications for metastatic urothelial carcinoma","volume":"10","author":"Contieri","year":"2024","journal-title":"Eur Urol Focus"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926001067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926001067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:29:42Z","timestamp":1778200182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926001067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1078143926001067"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111095","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concordance and prognostic value of antibody drug conjugate and checkpoint inhibition targets in matched bladder cancer specimens from transurethral resection of the bladder, radical cystectomy and lymphadenectomy","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}